Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Timothy S Maughan et al.   LANCET

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Richard A Adams et al.   LANCET ONCOLOGY

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

(2010) Michel Ducreux et al.   INTERNATIONAL JOURNAL OF CANCER

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

(2009) R A Adams et al.   BRITISH JOURNAL OF CANCER

Imputing missing covariate values for the Cox model

(2009) Ian R. White et al.   STATISTICS IN MEDICINE

Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin

(2008) Ivo M. Hennig et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials

(2008) Hendrik-Tobias Arkenau et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

(2008) Jim Cassidy et al.   JOURNAL OF CLINICAL ONCOLOGY